Luna Teams Up with UCI Health to Expand Access to Care with In-Home Outpatient Physical Therapy

Luna, the leading provider of in-home physical therapy, has teamed up with UCI Health, to expand access to patient care by providing in-home physical therapy across Orange County, California.

With a focus on evidence-based care, UCI Health is the only academic health system in Orange County and the clinical arm of the University of California, Irvine. Through the collaboration, UCI Health will leverage Luna’s platform to coordinate and deliver in-home physical therapy to patients.

Luna offers in-home physical therapy through its licensed therapists (more than 4,000 in 2022). It operates in 42 U.S. markets and 24 states, and partners with some of the most innovative health systems nationally, including Emory Healthcare, SCL Health, UCLA Health, and Scripps Health.

“Patients want and deserve the convenience and safety of in-home care, and our mission is aligned with that of UCI Health to improve access and quality of in-home physical therapy,” said Palak Shah, Luna co-founder and head of clinical operations. “We’re delivering a high standard of personalized and quality care for patients, while providing relief for health systems operating at capacity and needing more access.”

The Luna technology platform seamlessly matches patients to therapists based on specialty, geography, schedules, and other factors. Its broad network of local physical therapists will provide consistent, high-quality care, of the type administered in a traditional outpatient clinic, but from the comfort of a patient’s home.

The same therapist will coordinate with the patient until the end of the treatment plan, ensuring consistent and quality care. Between visits, patients use the Luna platform to communicate with their physical therapists, set appointment times, and perform therapist prescribed and monitored exercises.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”